Trevi Therapeutics, Inc. Stock News

Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non...

Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cas...

Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - S...

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn.

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Associate Professor Imran Satia will give a poster presentation on the patient-reported outcomes from the Phase 2a RIVER trial of nalbuphine ER for the treatment of ...

NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that...